ADCs Pipeline Update: Sutro Biopharma Presents Encouraging Data in Patients with Advanced Ovarian Cancer

Sutro Biopharma, a California based, clinical-stage company, announced initial safety data in ovarian cancer patients from its ongoing phase I study (NCT03748186) of STRO-002. The drug is a folate receptor alpha (FolRα)-targeting antibody-drug conjugate (ADC) and potent anti-tumor activity in preclinical endometrial cancer patient-derived xenograft (PDX) models.

The data are being presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 2019. 

As per a recent market report by Roots Analysis, in the ADCs clinical pipeline, HER2 has been observed to be the most prominent antigen being targeted by 17% of the ADC candidates. CD22 is another notable target antigen, which is being targeted by 7% of the candidates.

ADCs Pipeline Distribution by Target Antigen
ADCs Pipeline Distribution by Target Antigen

A detailed evaluation of the clinical pipeline highlights that the folate receptor alpha (FolRα)-targeting antibody-drug conjugates (ADC) are currently only being developed for ovarian cancer.

ADCs Pipeline Distribution by Target and Indication
ADCs Pipeline Distribution by Target and Indication

Overall, the ADC therapeutics market is projected to be close to $15 billion by 2030. To get more insights into the ADCs development pipeline, check out the Biopharma detailed report here.